Xenetic Biosciences (NASDAQ:XBIO) Trading Down 0.3% – Time to Sell?

Xenetic Biosciences, Inc. (NASDAQ:XBIO) was down 0.3% during trading on Tuesday . The stock traded as low as $3.00 and last traded at $3.08. Approximately 5,946 shares were traded during trading, a decline of 57% from the average daily volume of 13,713 shares. The stock had previously closed at $3.09.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Xenetic Biosciences in a research note on Monday, April 20th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock presently has an average rating of “Sell”.

Xenetic Biosciences Stock Performance

The firm has a market cap of $6.87 million, a PE ratio of -2.50 and a beta of 2.19. The firm’s 50-day moving average price is $3.12 and its two-hundred day moving average price is $2.66.

Xenetic Biosciences (NASDAQ:XBIO) last issued its quarterly earnings data on Tuesday, May 12th. The company reported ($0.20) earnings per share for the quarter. The company had revenue of $0.81 million for the quarter. Xenetic Biosciences had a negative return on equity of 39.28% and a negative net margin of 70.03%.

Institutional Trading of Xenetic Biosciences

A hedge fund recently bought a new stake in Xenetic Biosciences stock. DRW Securities LLC purchased a new stake in Xenetic Biosciences, Inc. (NASDAQ:XBIO) in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 13,824 shares of the company’s stock, valued at approximately $30,000. DRW Securities LLC owned about 0.60% of Xenetic Biosciences at the end of the most recent reporting period. Hedge funds and other institutional investors own 15.12% of the company’s stock.

About Xenetic Biosciences

Xenetic Biosciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of enhanced protein and peptide therapeutics for oncology, immunology and rare diseases. The company leverages its proprietary platforms to extend the half-life, improve the stability and optimize the delivery of biopharmaceuticals. Xenetic’s pipeline includes novel candidates designed to address unmet medical needs in solid tumors and inherited disorders.

At the heart of Xenetic’s technology portfolio are two complementary platforms: PolyXen, which employs a unique polysialylation process to prolong drug circulation and reduce immunogenicity, and Alphabody, a next-generation antibody-mimetic framework engineered for high-affinity binding to challenging targets.